1. Engel-Nitz NM, Alemayehu B, Parry D, et al. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res, 2011, 3: 233-245.
2. Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol, 2011, 23(4): 18.
3. 许江兰, 范立. 前列腺癌的放射治疗. 肿瘤研究与临床, 2008, 20(12): 861-863.
4. 喻彬, 须霆, 邹青, 等. 激素抵抗性前列腺癌化疗15例报告. 现代肿瘤医学, 2010, 18(4): 748-749.
5. 曲妍妍, 张永忠. 染料木黄酮生物活性及抗病机理的研究进展. 食品工业技术, 2010, 31(8): 364-369.
6. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to anti-androgin therapy. Nature Medicine, 2004, 10(1): 33-39.
7. 周志耀, 戴玉田. 前列腺肿瘤. 见: 吴阶平主编, 吴阶平泌尿外科学. 济南: 山东科技出版社, 2004: 1059-1091.
8. Mansoor TA, Ramalho RM, Luo X, et al. Isoflavones as apoptosis inducers in human hapatoma HuH-7 cells. Phytocher Res, 2011, 25(12): 1819-1824.
9. Ma Y, Wang J, Liu L, et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer Lett, 2011, 301(1): 75-84.
10. 凌航, 陈裕庆, 高美钦, 等. Genistein联合5-FU对人结肠癌细胞株(SW480)增殖与凋亡的影响. 中华肿瘤防治杂志, 2010, 17(12): 912-915.
11. Raynal NJ, Momparler L, Charbonneau M, et al. Antileukemic activity od Genistein, a major isoflavone present in soy products. J Nat Prod, 2008, 71(1): 3-7.
12. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: The innocent bystander scenario. Cell Death Differ, 2006, 13(8): 1396-1402.
13. Lucken-Ardjomande S, Martinou JC. Newcomers in the process of mitochondrial permeabilization. J Cell Sci, 2005, 118(pt 3): 473-483.
14. Nieminen AI, Partanen JI, Klefstrom J. c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle, 2007, 6(20): 2464-2472. |